Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTROs: Pembrolizumab Maintenance After Radiation for Oligometastatic RCC
NCT06004336Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2023
- Primary completion
- Jan 2029
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in renal cell carcinoma (RCC), sponsored by University of Texas MD Anderson Cancer Center. Started Oct 2023; status: recruiting.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT06004336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06004336.